Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2007

Biovail Gains License to Two Pharma Pass II Early-Stage Compounds

  • Biovail acquired the worldwide rights to two reportedly early-stage candidates from Pharma Pass II (PPII). BVF-068 is being investigated for the treatment of a central nervous system (CNS) disorder, and BVF-247 is a novel formulation of a cardiovascular agent, according to the companies.

    Biovail will develop, manufacture, and market both compounds. PPII will receive an upfront fee, milestone payments for each product, and tiered, single-digit royalties on net commercial sales.

    “These two products target large global markets and have the potential to address safety issues inherent in the currently marketed formulations,” points out Douglas Squires, Ph.D., Biovail's CEO.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »